AstraZeneca fights generic Nexium bid
pharmafile | November 25, 2005 | News story | Sales and Marketing |
AstraZeneca has filed a lawsuit in the US courts to block the launch of a generic version of Nexium.
The ulcer treatment is AstraZeneca's biggest selling brand, and is expected to earn the company around $4.5 billion this year – revenue the company is determined to protect.
Indian generics company Ranbaxy wants to launch its own version of the drug in the US, but AstraZeneca says it infringes six separate patents, which could provide it with market exclusivity up to 2019.
AstraZeneca recently filed a lawsuit to tackle a separate generic challenge to another of its leading brands, schizophrenia blockbuster Seroquel.
Related articles:
Oxford and GSK to collaborate on cancer research in India
Friday , November 18, 2005